{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T13:37:34Z","timestamp":1776087454871,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Dutch Kidney Foundation","doi-asserted-by":"crossref","award":["E.033"],"award-info":[{"award-number":["E.033"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002996","name":"Dutch Heart Foundation","doi-asserted-by":"crossref","award":["2001-005"],"award-info":[{"award-number":["2001-005"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The relationship between circulating total bilirubin and incident non-alcoholic fatty liver disease (NAFLD) is uncertain. We aimed to assess the association of total bilirubin with the risk of new-onset NAFLD and investigate any causal relevance to the association using a Mendelian randomization (MR) study. Plasma total bilirubin levels were measured at baseline in the PREVEND prospective study of 3824 participants (aged 28\u201375\u00a0years) without pre-existing cardiovascular disease or NAFLD. Incident NAFLD was estimated using the biomarker-based algorithms, fatty liver index (FLI) and hepatic steatosis index (HSI). Odds ratios (ORs) (95% confidence intervals) for NAFLD were assessed. The genetic variant rs6742078 located in the\u00a0UDP-glucuronosyltransferase (UGT1A1) locus was used as an instrumental variable. Participants were followed up for a mean duration of 4.2\u00a0years. The multivariable adjusted OR (95% CIs) for NAFLD as estimated by FLI (434 cases) was 0.82 (0.73\u20130.92; <jats:italic>p\u2009<\/jats:italic>=\u20090.001) per 1 standard deviation (SD) change in log<jats:sub>e<\/jats:sub> total bilirubin. The corresponding adjusted OR (95% CIs) for NAFLD as estimated by HSI (452 cases) was 0.87 (0.78\u20130.97; <jats:italic>p\u2009<\/jats:italic>=\u20090.012). The rs6742078 variant explained 20% of bilirubin variation. The ORs (95% CIs) for a 1 SD genetically elevated total bilirubin level was 0.98 (0.69\u20131.38; <jats:italic>p\u2009<\/jats:italic>=\u20090.900) for FLI and 1.14 (0.81\u20131.59; <jats:italic>p\u2009<\/jats:italic>=\u20090.451) for HSI. Elevated levels of total bilirubin were not causally associated with decreased risk of NAFLD based on MR analysis. The observational association may be driven by biases such as unmeasured confounding and\/or reverse causation. However, due to low statistical power, larger-scale investigations are necessary to draw definitive conclusions.<\/jats:p>","DOI":"10.1007\/s10654-019-00589-0","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T12:02:41Z","timestamp":1574769761000},"page":"123-137","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Circulating total bilirubin and risk of non-alcoholic fatty liver disease in the PREVEND study: observational findings and a Mendelian randomization study"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2625-0273","authenticated-orcid":false,"given":"Setor K.","family":"Kunutsor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Frysz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niek","family":"Verweij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyanne M.","family":"Kieneker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan J. L.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin P. F.","family":"Dullaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,26]]},"reference":[{"issue":"3","key":"589_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/ATVBAHA.114.304929","volume":"35","author":"SK Kunutsor","year":"2015","unstructured":"Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35(3):716\u201324. https:\/\/doi.org\/10.1161\/ATVBAHA.114.304929.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"589_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.006503","author":"SK Kunutsor","year":"2017","unstructured":"Kunutsor SK, Kieneker LM, Burgess S, Bakker SJL, Dullaart RPF. Circulating total bilirubin and future risk of hypertension in the general population: the prevention of renal and vascular end-stage disease (PREVEND) prospective study and a mendelian randomization approach. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/jaha.117.006503.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"589_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.diabet.2016.06.002","volume":"42","author":"J Nano","year":"2016","unstructured":"Nano J, Muka T, Cepeda M, et al. Association of circulating total bilirubin with the metabolic syndrome and type 2 diabetes: a systematic review and meta-analysis of observational evidence. Diabetes Metab. 2016;42(6):389\u201397. https:\/\/doi.org\/10.1016\/j.diabet.2016.06.002.","journal-title":"Diabetes Metab"},{"issue":"4","key":"589_CR4","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2337\/db14-0228","volume":"64","author":"A Abbasi","year":"2015","unstructured":"Abbasi A, Deetman PE, Corpeleijn E, et al. Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. Diabetes. 2015;64(4):1459\u201369. https:\/\/doi.org\/10.2337\/db14-0228.","journal-title":"Diabetes"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.exger.2015.09.014","volume":"72","author":"SK Kunutsor","year":"2015","unstructured":"Kunutsor SK. Serum total bilirubin levels and coronary heart disease\u2013causal association or epiphenomenon? Exp Gerontol. 2015;72:63\u20136. https:\/\/doi.org\/10.1016\/j.exger.2015.09.014.","journal-title":"Exp Gerontol"},{"issue":"1","key":"589_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2796.2012.02576.x","volume":"273","author":"S Stender","year":"2013","unstructured":"Stender S, Frikke-Schmidt R, Nordestgaard BG, Grande P, Tybjaerg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis. J Intern Med. 2013;273(1):59\u201368. https:\/\/doi.org\/10.1111\/j.1365-2796.2012.02576.x.","journal-title":"J Intern Med"},{"issue":"1","key":"589_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11892-008-0006-1","volume":"8","author":"SD Lidofsky","year":"2008","unstructured":"Lidofsky SD. Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment. Curr Diab Rep. 2008;8(1):25\u201330.","journal-title":"Curr Diab Rep"},{"issue":"6","key":"589_CR8","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313\u201321. https:\/\/doi.org\/10.1002\/hep.20701.","journal-title":"Hepatology"},{"issue":"11","key":"589_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.annepidem.2007.05.013","volume":"17","author":"LA Adams","year":"2007","unstructured":"Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17(11):863\u20139. https:\/\/doi.org\/10.1016\/j.annepidem.2007.05.013.","journal-title":"Ann Epidemiol"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33. https:\/\/doi.org\/10.1186\/1471-230X-6-33.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"589_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138. https:\/\/doi.org\/10.1016\/j.dld.2009.08.002.","journal-title":"Dig Liver Dis"},{"issue":"4","key":"589_CR12","doi-asserted-by":"publisher","first-page":"e0124749","DOI":"10.1371\/journal.pone.0124749","volume":"10","author":"S Jager","year":"2015","unstructured":"Jager S, Jacobs S, Kroger J, et al. Association between the fatty liver index and risk of type 2 diabetes in the EPIC-potsdam study. PLoS ONE. 2015;10(4):e0124749. https:\/\/doi.org\/10.1371\/journal.pone.0124749.","journal-title":"PLoS ONE"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fphar.2012.00055","volume":"3","author":"L Vitek","year":"2012","unstructured":"Vitek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55. https:\/\/doi.org\/10.3389\/fphar.2012.00055.","journal-title":"Front Pharmacol"},{"issue":"1","key":"589_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.01.001","volume":"198","author":"HA Schwertner","year":"2008","unstructured":"Schwertner HA, Vitek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. 2008;198(1):1\u201311. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.01.001.","journal-title":"Atherosclerosis"},{"key":"589_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-2423(06)43001-8","volume":"43","author":"L Vitek","year":"2007","unstructured":"Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem. 2007;43:1\u201357.","journal-title":"Adv Clin Chem"},{"issue":"9","key":"589_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.amjmed.2008.03.045","volume":"121","author":"TS Perlstein","year":"2008","unstructured":"Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999\u20132004. Am J Med. 2008;121(9):781\u20138. https:\/\/doi.org\/10.1016\/j.amjmed.2008.03.045.","journal-title":"Am J Med"},{"issue":"5","key":"589_CR17","doi-asserted-by":"publisher","first-page":"e37241","DOI":"10.1371\/journal.pone.0037241","volume":"7","author":"Y Chang","year":"2012","unstructured":"Chang Y, Ryu S, Zhang Y, et al. A cohort study of serum bilirubin levels and incident non-alcoholic fatty liver disease in middle aged Korean workers. PLoS ONE. 2012;7(5):e37241. https:\/\/doi.org\/10.1371\/journal.pone.0037241.","journal-title":"PLoS ONE"},{"issue":"6","key":"589_CR18","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1542\/peds.2008-3087","volume":"124","author":"YC Lin","year":"2009","unstructured":"Lin YC, Chang PF, Hu FC, Chang MH, Ni YH. Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease. Pediatrics. 2009;124(6):e1221\u20137. https:\/\/doi.org\/10.1542\/peds.2008-3087.","journal-title":"Pediatrics"},{"issue":"4","key":"589_CR19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3350\/cmh.2012.18.4.383","volume":"18","author":"MS Kwak","year":"2012","unstructured":"Kwak MS, Kim D, Chung GE, et al. Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease. Clin Mol Hepatol. 2012;18(4):383\u201390. https:\/\/doi.org\/10.3350\/cmh.2012.18.4.383.","journal-title":"Clin Mol Hepatol"},{"key":"589_CR20","doi-asserted-by":"publisher","first-page":"31006","DOI":"10.1038\/srep31006","volume":"6","author":"J Tian","year":"2016","unstructured":"Tian J, Zhong R, Liu C, et al. Association between bilirubin and risk of non-alcoholic fatty liver disease based on a prospective cohort study. Sci Rep. 2016;6:31006. https:\/\/doi.org\/10.1038\/srep31006.","journal-title":"Sci Rep"},{"issue":"12","key":"589_CR21","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1365-2036.2012.05114.x","volume":"35","author":"M Hjelkrem","year":"2012","unstructured":"Hjelkrem M, Morales A, Williams CD, Harrison SA. Unconjugated hyperbilirubinemia is inversely associated with non-alcoholic steatohepatitis (NASH). Aliment Pharmacol Ther. 2012;35(12):1416\u201323. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05114.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"589_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.soard.2011.06.010","volume":"8","author":"J Chisholm","year":"2012","unstructured":"Chisholm J, Seki Y, Toouli J, Stahl J, Collins J, Kow L. Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery. Surg Obes Relat Dis. 2012;8(4):416\u201322. https:\/\/doi.org\/10.1016\/j.soard.2011.06.010.","journal-title":"Surg Obes Relat Dis"},{"issue":"22","key":"589_CR23","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1161\/CIRCULATIONAHA.112.114066","volume":"126","author":"LJ Horsfall","year":"2012","unstructured":"Horsfall LJ, Nazareth I, Petersen I. Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation. 2012;126(22):2556\u201364. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.114066.","journal-title":"Circulation"},{"issue":"22","key":"589_CR24","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1161\/CIRCULATIONAHA.112.147082","volume":"126","author":"J Seppen","year":"2012","unstructured":"Seppen J, Bosma P. Bilirubin, the gold within. Circulation. 2012;126(22):2547\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.147082.","journal-title":"Circulation"},{"issue":"1","key":"589_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/ije\/dyu242","volume":"44","author":"L Wang","year":"2015","unstructured":"Wang L, Bautista LE. Serum bilirubin and the risk of hypertension. Int J Epidemiol. 2015;44(1):142\u201352. https:\/\/doi.org\/10.1093\/ije\/dyu242.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"589_CR26","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/ije\/31.4.730","volume":"31","author":"B Keavney","year":"2002","unstructured":"Keavney B. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol. 2002;31(4):730\u20136.","journal-title":"Int J Epidemiol"},{"issue":"5","key":"589_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/aje\/kwi224","volume":"162","author":"DB Petitti","year":"2005","unstructured":"Petitti DB, Freedman DA. Invited commentary: how far can epidemiologists get with statistical adjustment? Am J Epidemiol. 2005;162(5):415\u20138. https:\/\/doi.org\/10.1093\/aje\/kwi224(discussion 9\u201320).","journal-title":"Am J Epidemiol"},{"issue":"4","key":"589_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/oxfordjournals.aje.a010013","volume":"150","author":"R Clarke","year":"1999","unstructured":"Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150(4):341\u201353.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"589_CR29","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/ije\/dyl233","volume":"35","author":"C Fibrinogen Studies","year":"2006","unstructured":"Fibrinogen Studies C, Wood AM, White I, Thompson SG, Lewington S, Danesh J. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol. 2006;35(6):1570\u20138. https:\/\/doi.org\/10.1093\/ije\/dyl233.","journal-title":"Int J Epidemiol"},{"issue":"13","key":"589_CR30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1001\/jamainternmed.2013.6465","volume":"173","author":"S Stender","year":"2013","unstructured":"Stender S, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Extreme bilirubin levels as a causal risk factor for symptomatic gallstone disease. JAMA Intern Med. 2013;173(13):1222\u20138. https:\/\/doi.org\/10.1001\/jamainternmed.2013.6465.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"589_CR31","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"589_CR32","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.atherosclerosis.2014.12.045","volume":"238","author":"SK Kunutsor","year":"2014","unstructured":"Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP. Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis. 2014;238(2):356\u201364. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.12.045.","journal-title":"Atherosclerosis"},{"issue":"8","key":"589_CR33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehm062","volume":"28","author":"SE Borggreve","year":"2007","unstructured":"Borggreve SE, Hillege HL, Dallinga-Thie GM, et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J. 2007;28(8):1012\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehm062.","journal-title":"Eur Heart J"},{"issue":"2","key":"589_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.atherosclerosis.2009.07.042","volume":"208","author":"RP Dullaart","year":"2010","unstructured":"Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ, Group PS. High plasma lecithin:cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis. 2010;208(2):537\u201342. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.07.042.","journal-title":"Atherosclerosis"},{"issue":"6","key":"589_CR35","doi-asserted-by":"publisher","first-page":"e39110","DOI":"10.1371\/journal.pone.0039110","volume":"7","author":"JP Corsetti","year":"2012","unstructured":"Corsetti JP, Bakker SJ, Sparks CE, Dullaart RP. Apolipoprotein A-II influences apolipoprotein E-linked cardiovascular disease risk in women with high levels of HDL cholesterol and C-reactive protein. PLoS ONE. 2012;7(6):e39110. https:\/\/doi.org\/10.1371\/journal.pone.0039110.","journal-title":"PLoS ONE"},{"issue":"1","key":"589_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367(1):20\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1114248.","journal-title":"N Engl J Med"},{"key":"589_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2261-12-16","volume":"12","author":"PF McArdle","year":"2012","unstructured":"McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. BMC Cardiovasc Disord. 2012;12:16. https:\/\/doi.org\/10.1186\/1471-2261-12-16.","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"589_CR38","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10654-011-9606-1","volume":"26","author":"RH Groenwold","year":"2011","unstructured":"Groenwold RH, Klungel OH, Grobbee DE, Hoes AW. Selection of confounding variables should not be based on observed associations with exposure. Eur J Epidemiol. 2011;26(8):589\u201393. https:\/\/doi.org\/10.1007\/s10654-011-9606-1.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"589_CR39","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/ije\/dyq151","volume":"40","author":"BL Pierce","year":"2011","unstructured":"Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740\u201352. https:\/\/doi.org\/10.1093\/ije\/dyq151.","journal-title":"Int J Epidemiol"},{"issue":"12","key":"589_CR40","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1124\/dmd.110.035345","volume":"38","author":"CJ Gallagher","year":"2010","unstructured":"Gallagher CJ, Balliet RM, Sun D, Chen G, Lazarus P. Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos. 2010;38(12):2204\u20139. https:\/\/doi.org\/10.1124\/dmd.110.035345.","journal-title":"Drug Metab Dispos"},{"issue":"9001","key":"589_CR41","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S0140-6736(96)91273-8","volume":"347","author":"G Monaghan","year":"1996","unstructured":"Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert\u2019s syndrome. Lancet. 1996;347(9001):578\u201381.","journal-title":"Lancet"},{"issue":"4 Pt 1","key":"589_CR42","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/jhep.2000.18193","volume":"32","author":"J Borlak","year":"2000","unstructured":"Borlak J, Thum T, Landt O, Erb K, Hermann R. Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert\u2019s syndrome) in healthy subjects. Hepatology. 2000;32(4 Pt 1):792\u20135. https:\/\/doi.org\/10.1053\/jhep.2000.18193.","journal-title":"Hepatology"},{"issue":"6 Pt 1","key":"589_CR43","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/clinchem\/45.6.897","volume":"45","author":"ML Biondi","year":"1999","unstructured":"Biondi ML, Turri O, Dilillo D, Stival G, Guagnellini E. Contribution of the TATA-box genotype (Gilbert syndrome) to serum bilirubin concentrations in the Italian population. Clin Chem. 1999;45(6 Pt 1):897\u20138.","journal-title":"Clin Chem"},{"issue":"1","key":"589_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.tips.2015.09.003","volume":"37","author":"NG Abraham","year":"2016","unstructured":"Abraham NG, Junge JM, Drummond GS. Translational significance of heme oxygenase in obesity and metabolic syndrome. Trends Pharmacol Sci. 2016;37(1):17\u201336. https:\/\/doi.org\/10.1016\/j.tips.2015.09.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"25","key":"589_CR45","doi-asserted-by":"publisher","first-page":"16093","DOI":"10.1073\/pnas.252626999","volume":"99","author":"DE Baranano","year":"2002","unstructured":"Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA. 2002;99(25):16093\u20138. https:\/\/doi.org\/10.1073\/pnas.252626999.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"589_CR46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0304-4165(93)90013-X","volume":"1158","author":"T Nakagami","year":"1993","unstructured":"Nakagami T, Toyomura K, Kinoshita T, Morisawa S. A beneficial role of bile pigments as an endogenous tissue protector: anti-complement effects of biliverdin and conjugated bilirubin. Biochim Biophys Acta. 1993;1158(2):189\u201393.","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"589_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.molmed.2006.10.001","volume":"12","author":"LA Videla","year":"2006","unstructured":"Videla LA, Rodrigo R, Araya J, Poniachik J. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease. Trends Mol Med. 2006;12(12):555\u20138. https:\/\/doi.org\/10.1016\/j.molmed.2006.10.001.","journal-title":"Trends Mol Med"},{"issue":"3","key":"589_CR48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","volume":"149","author":"J du Plessis","year":"2015","unstructured":"du Plessis J, van Pelt J, Korf H, et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology. 2015;149(3):635\u201348. https:\/\/doi.org\/10.1053\/j.gastro.2015.05.044.","journal-title":"Gastroenterology"},{"issue":"14","key":"589_CR49","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.106.633206","volume":"114","author":"JP Lin","year":"2006","unstructured":"Lin JP, O\u2019Donnell CJ, Schwaiger JP, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006;114(14):1476\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.633206.","journal-title":"Circulation"},{"issue":"5","key":"589_CR50","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/CIRCULATIONAHA.112.105775","volume":"126","author":"T Maruhashi","year":"2012","unstructured":"Maruhashi T, Soga J, Fujimura N, et al. Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation. 2012;126(5):598\u2013603. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.105775.","journal-title":"Circulation"},{"issue":"3","key":"589_CR51","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. https:\/\/doi.org\/10.1371\/journal.pmed.1001779.","journal-title":"PLoS Med"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-019-00589-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10654-019-00589-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-019-00589-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:56:25Z","timestamp":1606265785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10654-019-00589-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,26]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s10654-019-00589-0","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,26]]},"assertion":[{"value":"12 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}